| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/27/2004 | US6727266 Substituted tryptophan derivatives |
| 04/27/2004 | US6727260 Using compounds capable of inhibiting the activity of a proton-gated cation channel in therapy or aleviation of diseases or disorders associated with, or mediated by a drop in extracellular ph |
| 04/27/2004 | US6727258 Allosteric adenosine receptor modulators |
| 04/27/2004 | US6727255 Brain, nervous system and psychological disorders |
| 04/27/2004 | US6727254 8-(bis-(phenyl) methyl)-3-heteroaryl-8-azabicyclo-(3.2.1)octan-3-ols and derivatives, useful in treating pain, anxiety, cough, asthma, depresion and alcohol abuse |
| 04/27/2004 | US6727251 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 04/27/2004 | US6727247 Adenosine receptor ligands in a method of treatment, control, or prevention of central nervous system disorders |
| 04/27/2004 | US6727246 Enhancement of cognition and memory in human diseases such as alzheimer's |
| 04/27/2004 | US6727244 Mammalian metabolites of a tachykinin receptor antagonist |
| 04/27/2004 | US6727242 Pharmacological treatment for sleep apnea |
| 04/27/2004 | US6727239 Inhibitory activity on no- synthase enzymes producing nitrogen monoxide no and/or an activity which traps the reactive oxygen species (ros) |
| 04/27/2004 | US6727231 Effective to improve one or more of the symptoms of autistic disorder |
| 04/27/2004 | US6727226 Conotoxin peptide extracted from the venom of a marine snail, conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics |
| 04/27/2004 | US6727075 Measuring lipid peroxidation in mammals; obtain tissue or fluid sample evaluate the concentration of prostaglandin isomer marker present, compare to control, amplified concentration of the marker indicates oxidative stress |
| 04/27/2004 | US6726935 Secreted from venom gland of a toad; formulated as ointment, suspension, gel, spray, patch or solution; for preventing premature, noncontrolled ejaculation and/or sexual hypersensitivity |
| 04/27/2004 | US6726919 For inducing or maintaining anesthesia or sedation in a patient |
| 04/27/2004 | CA2299400C Method for treating disease-related or drug-induced dyskinesias |
| 04/27/2004 | CA2140368C (3r,4r)-.delta.6-tetrahydrocannabinol-7-oic acids |
| 04/27/2004 | CA2118929C (3s,4s)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them |
| 04/22/2004 | WO2004033691A2 Human lipid phosphate phosphatases and uses thereof for treating neuronal diseases |
| 04/22/2004 | WO2004033686A1 Novel protein and dna thereof |
| 04/22/2004 | WO2004033652A2 Inhibitors of fatty acid amide hydrolase |
| 04/22/2004 | WO2004033498A2 .pharmaceutical composition comprising ht4d100a receptors, and therapeutic uses thereof |
| 04/22/2004 | WO2004033458A1 Amidine compounds |
| 04/22/2004 | WO2004033456A2 1,4-diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof related to malfunction of nicotinic receptors |
| 04/22/2004 | WO2004033453A1 Substituted c-imidazo[1,2-a]pyridin-3-yl-methylamines |
| 04/22/2004 | WO2004033448A2 Isolation, purification and synthesis of procyanidin b2 and uses thereof |
| 04/22/2004 | WO2004033439A1 Thiazole compounds for the treatment of neurodegenerative disorders |
| 04/22/2004 | WO2004033434A1 Pyrazole compounds for treatment of neurodegenerative disorders |
| 04/22/2004 | WO2004033426A2 Heteroaryl propyl-piperazines and heteroaryl propyl-piperidines serving as dopaminergic and serotoninergic agents |
| 04/22/2004 | WO2004032955A1 Inhibitors for continuous activation of calcineurin |
| 04/22/2004 | WO2004032938A1 Use of dihydroimidazolones for the treatment of epilepsy in dogs |
| 04/22/2004 | WO2004032934A1 Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons |
| 04/22/2004 | WO2004032932A1 Use of 5-ht2 receptor antagonists for the treatment of sleep disorders |
| 04/22/2004 | WO2004032922A1 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist |
| 04/22/2004 | WO2004032917A1 Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction |
| 04/22/2004 | WO2004032916A1 A composition comprising selegeline, procaine, vinpocetine, trimethylglycinean and a n-gaba ingredient for treating neurodegenerative disorders |
| 04/22/2004 | WO2004032913A1 Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration |
| 04/22/2004 | WO2004032836A2 Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors |
| 04/22/2004 | WO2004022544A8 Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same |
| 04/22/2004 | WO2004020430A3 Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics |
| 04/22/2004 | WO2004018431A3 Novel phenanthridines |
| 04/22/2004 | WO2004017941A3 Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist |
| 04/22/2004 | WO2004016597A3 Protein kinase inhibitors and uses thereof |
| 04/22/2004 | WO2004014300A3 Tyrosine kinase inhibitors |
| 04/22/2004 | WO2004013077A3 Cyclopentanone and cyclopentanone derivatives as potent activators of hsf-1 |
| 04/22/2004 | WO2004011031A9 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| 04/22/2004 | WO2004010945A3 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 04/22/2004 | WO2004009784A3 Novel inhibitors of kinases |
| 04/22/2004 | WO2004007696A3 Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| 04/22/2004 | WO2004005243A3 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives |
| 04/22/2004 | WO2004002986A3 Novel benzimidazole derivatives |
| 04/22/2004 | WO2004000313A3 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds |
| 04/22/2004 | WO2003101958A3 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| 04/22/2004 | WO2003093499A3 Therapeutic use of selective pde10 inhibitors |
| 04/22/2004 | WO2003078403A3 Derives d’aminoindazoles comme inhibiteurs de proteine-kinase |
| 04/22/2004 | WO2003072106A3 Use of tyrosine kinase inhibitors for treating substance use disorders |
| 04/22/2004 | WO2003070965A8 The eaat2 promoter and uses thereof |
| 04/22/2004 | WO2003068937A3 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
| 04/22/2004 | WO2003061563A3 Method of preparing delta-9 tetrahydrocannabinol |
| 04/22/2004 | WO2003046565A3 Ig lambda biopolymer markers predictive of alzheimers disease |
| 04/22/2004 | WO2003040345A3 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/22/2004 | WO2003026563A9 Conjugated anti-psychotic drugs and uses thereof |
| 04/22/2004 | WO2003005999A8 Methods of treating cytokine mediated diseases |
| 04/22/2004 | WO2002098857A8 New indole derivatives with 5-ht6 receptor affinity |
| 04/22/2004 | WO2002094794A8 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders |
| 04/22/2004 | WO2002074767A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074752A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074748A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002064731A9 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 04/22/2004 | WO2002062970A8 Enteric nervous system derived stem and progenitor cells and uses thereof |
| 04/22/2004 | WO2001082949A9 Method of reducing side effects of chemotherapy in cancer patients |
| 04/22/2004 | US20040078835 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 04/22/2004 | US20040077896 Compounds for the treatment of metabolic disorders |
| 04/22/2004 | US20040077877 Jun n-terminal kinase inhibitors |
| 04/22/2004 | US20040077875 (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer |
| 04/22/2004 | US20040077861 Asymmetric addition of organometallic compounds to chiral sulfinimine to give adducts in predominantly one diastereomer can subsequently be transferred into pure enantiomers of by cleavage of the chiral auxilliary |
| 04/22/2004 | US20040077854 4-chloro-N-((5-((4-(hexylamino)piperidin-1-yl)sulfonyl)thien-2 -yl)methyl)benzamide for example; JUN kinase inhibitors to treat nervous system disorders, cancer, cardiovascular and autoimmune disorders |
| 04/22/2004 | US20040077851 Receptor selective cannabimimetic aminoalkylindoles |
| 04/22/2004 | US20040077837 Microtubule-associated proteins and tubulins |
| 04/22/2004 | US20040077719 Food supplements, feed additives, dietetic, cosmetics |
| 04/22/2004 | US20040077706 Piperidine and azepine derivatives; anxiolytic, analgesic, antidepressant, antiemetic, antiinflammatory, and hypotensive agents; sexual and psychological disorders; Alzheimer*s, Parkinson*s, Lesche-Nyhane, Wilson*s, and Tourette*s syndrome |
| 04/22/2004 | US20040077702 Administering indazole derivative; or thienyl-, furyl-, or pyrrolyl- fused pyrazole derivative to treat Alzheimer*s, Parkinson*s, or Huntington*s disease |
| 04/22/2004 | US20040077701 Pyrazole derivates for treatment of osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer*s disease |
| 04/22/2004 | US20040077695 Anticarcinogenic, antiallergen, and antiinflammatory agents; autoimmuned diseases |
| 04/22/2004 | US20040077693 Integrin receptor inhibitors |
| 04/22/2004 | US20040077681 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 04/22/2004 | US20040077678 Urea substituted imidazoquinoline ethers |
| 04/22/2004 | US20040077670 Novel sulfamides and their use as endothelin receptor antagonists |
| 04/22/2004 | US20040077667 Quinazolinone derivatives |
| 04/22/2004 | US20040077663 Thienopyrimidine-based inhibitors of the src family |
| 04/22/2004 | US20040077658 Respiratory system, nervous system, brain, gastrointestinal and psychological disorders; chronic obstructive pulmonary disease; antiasthmatics, analgesics |
| 04/22/2004 | US20040077657 HT3 Receptor antagonists; amyotrophic lateral sclerosis, premenstrual tension, obsessive-compulsive disorder; Parkinson*s, Alzheimer*s, and Huntington*s disease; memory, eating, psychological, and nervous system disorders |
| 04/22/2004 | US20040077653 GABAA (gamma-aminobutyric acid) receptor modulators; anxiolytic, antidepresant agents; attention deficit disorder, Alzheimer*s disease treatment; central nervous systmem disorders |
| 04/22/2004 | US20040077649 Novel cannabimimetic ligands |
| 04/22/2004 | US20040077644 Administering quinoline derivative as analgesic |
| 04/22/2004 | US20040077643 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient |
| 04/22/2004 | US20040077642 Pyrimidine compounds |
| 04/22/2004 | US20040077640 Sodium channel modulators derived from 2-piperidylimidazoles |
| 04/22/2004 | US20040077636 Administering alpha-2 adrenergic receptor agonists including guanabenz, clonidine, lofexidine, and/or salt; preventing stress-induced seeking of ethanol or nicotine; drug abuse, drug dependence |